Update in the Treatment of Retinopathy of Prematurity

Am J Perinatol. 2022 Jan;39(1):22-30. doi: 10.1055/s-0040-1713181. Epub 2020 Jun 16.

Abstract

Retinopathy of prematurity (ROP) is an alteration in the development of the immature retina vascularization that frequently occurs in premature infants and is one of the leading causes of childhood blindness worldwide. In threshold stage retinopathy, laser photocoagulation is the standard treatment, particularly in those located in zone II. However, this therapy destroys parts of the retina and can lead to significant eye complications later in life. For this reason, in the last few years, antivascular endothelial growth factor agents are being used as monotherapy or as coadjuvant with laser, especially in retinopathy located in zone I. More recently, the administration of oral propranolol has been used as prevention and/or treatment of prethreshold retinopathy with encouraging results. This review provides an overview of the current evidence on newer treatment strategies for ROP. KEY POINTS: · Laser is the standard treatment in threshold retinopathy of prematurity (ROP).. · Prethreshold stages of the ROP have no treatment.. · Propranolol may prevent the progression of ROP..

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Disease Progression
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Laser Coagulation* / adverse effects
  • Oxygen Inhalation Therapy
  • Propranolol / therapeutic use*
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*
  • Retinopathy of Prematurity / drug therapy
  • Retinopathy of Prematurity / surgery
  • Retinopathy of Prematurity / therapy*

Substances

  • Adrenergic beta-Antagonists
  • Bevacizumab
  • Propranolol
  • Receptors, Vascular Endothelial Growth Factor